Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for PTSD
Key facts
- Who runs it
- Neurovalens Ltd.
- Where
- San Diego, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 383 people enrolled
- Started
- 13 Feb 2023
- Ended
- 2 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Modius Spero active device
- Sham device
- Record updated
- 4 June 2025
Who can take part
- Age
- 22 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 36 criteriaShow less
Who can take part
- Signed informed consent
- Diagnosed PTSD by a medical practitioner
- Post-Traumatic Checklist (PCL-5) score or 31 or above
- Eligibility confirmed via the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
- Male or female, age ≥ 22 years and ≤ 80 years at the time of signing informed consent
- Ability and willingness to complete all study visits and procedures, including completion of mental health questionnaires
- Ability and willingness to adhere to 30 minutes usage of the device daily for the duration of the trial
- Agreement not to start any new PTSD, mental health, or insomnia medications for the duration of the trial and/or to inform the study team if intending on starting any new PTSD, mental health, or insomnia medications
- Agreement not to change any PTSD specific treatments for the duration of the trial e.g cognitive processing therapy
- Agreement not to undergo any significant lifestyle changes that may affect sleep (e.g. excessive exercise, sleep interventions etc.) for the duration of the trial
- Agreement not to use sleep trackers (e.g. Fitbit) for the duration of the trial
- Agreement not to travel across different time zones for the duration of the trial
- Access to Wi-Fi (for app to be able to upload usage data)
- Access to computer, laptop, iPad or tablet (to conduct remote study visits and complete study questionnaires remotely)
- Screening review by PTSD physician (study PI)
- Willingness to download and use a video platform (e.g Zoom) to conduct remote study visits
- Willingness to engage weekly with your Clinical Trial Mentor (CTM)
Who cannot take part
- Taking H2-receptor antagonist medication
- Previous use of Modius device
- History of skin breakdown, eczema, or other dermatological condition (e.g., psoriasis) affecting the skin behind the ears
- History of severe tinnitus or vertigo
- History or presence of malignancy within the last year
- History of chronic viral infection that causes vestibular neuropathy (e.g., hepatitis or HIV)
- A history of stroke or severe head injury as defined by a head injury that required a craniotomy or endotracheal intubation (in case this damaged the neurological pathways involved in vestibular stimulation)
- Diagnosis of epilepsy
- Failure to agree to use of device daily during study participation
- Any other medical condition, or medication use, that in the opinion of the PI is likely to make the subject refractory to VeNS
- Use of beta-blockers within 1 month of starting the study
- Use of antihistamines
- Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.)
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method
- Diagnosis of active migraines
- Participation in other research studies sponsored by Neurovalens
- Participation in any other PTSD studies
- Not fluent in English language
- Have a member of the same household who is currently participating in this study
Where in United States
- VA San Diego Healthcare SystemSan Diego, United States
About the trial
What the trial wants to find out
Trial title: A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to a Sham Control for Treatment of PTSD
Read full original descriptionShow less
The aim of this study: To better evaluate the efficacy of non-invasive electrical vestibular nerve stimulation (VeNS) as a method of treating PTSD, as compared to a sham control.
Allocation: Randomized to either active device or control device usage.
Endpoint classification: Efficacy Study Intervention Model: Parallel Assignment in 1:1 active to control allocation
Sample size: The aim is to recruit a total of up to 400 participants. The study will last 12 weeks in total for each subject.
The 2 groups in the trial
- Active VeNSExisting treatment, for comparison
The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
Treatment: Modius Spero active device
- Sham VeNSSham treatment, for comparison
The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
Treatment: Sham device
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to a Sham Control for Treatment of Post- Traumatic Stress Disorder (PTSD)
- Record updated
- 4 June 2025